CDK1 and breast cancer: Previous studies have confirmed that anticancer drugs can block mitotic progression by inhibiting the activity of the CDK1/Cyclin B complex, thereby inducing G2/M phase arrest, leading to a significant increase in the G2/M population and suppressing breast cancer cell proliferation [47,48,49,50].